PT  - JOURNAL ARTICLE
AU  - Rao, Suchitra
AU  - Lee, Grace M.
AU  - Razzaghi, Hanieh
AU  - Lorman, Vitaly
AU  - Mejias, Asuncion
AU  - Pajor, Nathan M.
AU  - Thacker, Deepika
AU  - Webb, Ryan
AU  - Dickinson, Kimberley
AU  - Bailey, L. Charles
AU  - Jhaveri, Ravi
AU  - Christakis, Dimitri A.
AU  - Bennett, Tellen D.
AU  - Chen, Yong
AU  - Forrest, Christopher B.
TI  - Clinical features and burden of post-acute sequelae of SARS-CoV-2 infection in children and adolescents: an exploratory EHR-based cohort study from the RECOVER program
AID  - 10.1101/2022.05.24.22275544
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.05.24.22275544
4099  - http://medrxiv.org/content/early/2022/05/25/2022.05.24.22275544.short
4100  - http://medrxiv.org/content/early/2022/05/25/2022.05.24.22275544.full
AB  - Importance The post-acute sequelae of SARS-CoV-2 (PASC) has emerged as a long-term complication in adults, but current understanding of the clinical presentation of PASC in children is limited.Objective To identify diagnosed symptoms, diagnosed health conditions and medications associated with PASC in children.Design, Setting and Participants Retrospective cohort study using electronic health records from 9 US children’s hospitals for individuals <21 years-old who underwent reverse transcriptase polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 between March 1, 2020 – October 31, 2021 and had at least 1 encounter in the 3 years before testing.Exposure SARS-CoV-2 PCR positivity.Main Outcomes and Measures We identified syndromic (symptoms), systemic (conditions), and medication PASC features in the 28-179 days following the initial test date. Adjusted hazard ratios (aHRs) were obtained for 151 clinically predicted PASC features by contrasting PCR-positive with PCR-negative groups using proportional hazards models, adjusting for site, age, sex, testing location, race/ethnicity, and time-period of cohort entrance. We estimated the incidence proportion for any syndromic, systemic or medication PASC feature in the two groups to obtain a burden of PASC estimate.Results Among 659,286 children in the study sample, 59,893 (9.1%) tested positive by PCR for SARS-CoV-2. Most were tested in outpatient testing facility (50.3%) or office (24.6%) settings. The most common syndromic, systemic, and medication features were loss of taste or smell (aHR 1.96 [95% CI 1.16-3.32), myocarditis (aHR 3.10 [95% CI 1.94-4.96]), and cough and cold preparations (aHR 1.52 [95% CI 1.18-1.96]). The incidence of at least one systemic/syndromic/medication feature of PASC was 41.9% among PCR-positive children versus 38.2% among PCR-negative children, with an incidence proportion difference of 3.7% (95% CI 3.2-4.2%). A higher strength of association for PASC was identified in those cared for in the ICU during the acute illness phase, children less than 5 years-old, and individuals with complex chronic conditions.Conclusions and Relevance In this large-scale, exploratory study, the burden of pediatric PASC that presented to health systems was low. Myocarditis was the most commonly diagnosed PASC-associated condition. Acute illness severity, young age, and comorbid complex chronic disease increased the risk of PASC.Question What are the incidence and clinical features of post-acute sequelae of SARS-CoV-2 infection (PASC) in children?Findings In this retrospective cohort study of 659,286 children tested for SARS-CoV-2 by polymerase chain reaction (PCR), the symptom, condition and medication with the strongest associations with SARS-CoV-2 infection were loss of taste/smell, myocarditis, and cough and cold preparations. The incidence proportion of non-MIS-C related PASC in the PCR-positive group exceeded the PCR-negative group by 3.7% (95% CI 3.2-4.2), with increased rates associated with acute illness severity, young age, and medical complexity.Meaning PASC in children appears to be uncommon, with features that differ from adults.Competing Interest StatementDr. Mejias reports funding from Janssen, Merck for research support, and Janssen, Merck and Sanofi-Pasteur for Advisory Board participation; Dr. Rao reports prior grant support from GSK and Biofire and is a consultant for Sequiris. Dr. Chen receives consulting support from GSK. Dr. Jhaveri is a consultant for AstraZeneca, Seqirus and Dynavax, and receives an editorial stipend from Elsevier. All other authors have no conflicts of interest to disclose.Funding StatementThis research was funded by the National Institutes of Health (NIH) Agreement OT2HL161847-01 as part of the Researching COVID to Enhance Recovery (RECOVER) program of research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Childrens Hospital of Philadelphia Institutional Review Board designated this study as not human subjects research and waived informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors https://github.com/PEDSnet/PASC PASCpost-acute sequelae of SARS-CoV-2 infectionCOVID-19coronavirus disease 2019SARS-CoV-2severe acute respiratory syndrome coronavirus 2PCRpolymerase chain reactionEHRelectronic health recordaHRadjusted hazard ratio;MIS-Cmultisystem inflammatory syndrome in childrenEDemergency departmentUCurgent careCIconfidence intervalsICD-10International Classification of Diseases, version 10